Hosted on MSN

Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.
Reuters

Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche (ROG.S), opens new tab said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in ...
Seeking Alpha

Roche posts late-stage trial wins for new multiple sclerosis therapy

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...
European Medical Journal

Five Year Outcomes of Ublituximab in Multiple Sclerosis

Ublituximab shows five year relapse reduction and disability benefits in multiple sclerosis, supporting early high efficacy ...